14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
REGN vs INSM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas INSM carries 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin).
Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Competes within the Biotechnology value chain with $26.3B market capitalization and -41.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ REGN vs INSM Key Questions & Quantitative Answers
As of Nov 19, 2026, Regeneron Pharmaceuticals Inc (REGN) is the stronger overall head-to-head candidate over Insmed, Inc. (INSM) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). REGN carries a Unified Composite Score of 42.6/100 (HOLD) at $923.34 (14.9x Forward P/E, 30.4% operating margin), whereas INSM carries 35.9/100 (SELL) at $144.46 (N/M Forward P/E, -41.7% operating margin). Growth vs. Quality Trade-Off: REGN earns the overall head-to-head edge with a stronger Unified Composite Score (42.6/100 HOLD vs. INSM 35.9/100 SELL) and 0.32β · 55% Vol risk profile, whereas INSM leads top-line expansion (+268.4% YoY revenue growth, 1.09x PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
REGN leads the Growth & Scale pillar: REGN posts +36.3% YoY revenue growth and +35.5% YoY earnings growth on $16.9B TTM revenue (46.7% gross margin, 30.4% operating margin), compared with INSM at +268.4% YoY revenue growth and +0.0% YoY earnings growth on $1.52B TTM revenue (84.4% gross margin, -41.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), REGN cumulative revenue shifted +178.4% while INSM shifted +6000.0%. In operating R&D and SG&A reinvestment, REGN deploys 16.3% of Rev ($2.75B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INSM.
REGN screens cheaper on headline valuation multiples. REGN trades at 14.9x Forward P/E, 20.9x Trailing P/E, 1.15x PEG, and 5.7x EV/Revenue (21.5% FCF margin), whereas INSM trades at N/M Forward P/E, 107.5x Trailing P/E, 1.09x PEG, and 17.4x EV/Revenue (-41.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against REGN (14.9% ROE) versus INSM (-72.5% ROE) capital efficiency.
In options market volatility and institutional positioning, REGN carries 35.5% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 55% Vol realized risk). By comparison, INSM carries 52.5% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.16x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.40β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.